Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 10 Feb 2025 Planned initiation date changed from 6 Jan 2025 to 6 Feb 2025.
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.
- 16 Jan 2025 New trial record